Gordafaried Deyanat‐Yazdi

Author

Kyoto University

Also Known As

Deyanat-Yazdi, G., Gordafaried Deyanat-Yazdi, Gordafaried Deyanat‐Yazdi

Publications

578

Citations

H-Index

Concepts

All Affiliations

Kyoto University Tokyo University of Pharmacy and Life Sciences Bristol-Myers Squibb (Switzerland)Kyoto Pharmaceutical University

About

Gordafaried Deyanat‐Yazdi is an author at Kyoto University specializing in medicine, drug discovery, and drug development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	517
2	Natural Sciences	3	3	426
3	Biochemistry	3	3	426
4	Cell Biology	2	2	91
5	Health Sciences	1	1	32

Gordafaried Deyanat‐Yazdi

Publications

569

Citations

H-Index

Page 1

	Year	Citations
Structure−Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor Venkat R. Macherla, Scott S. Mitchell, Rama Rao Manam, Journal of Medicinal Chemistry Proteasome InhibitionMedicinal ChemistryPharmaceutical ChemistryBiochemistrySalinosporamide A	2005	235
Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure Yuri Yamazaki, Koji Tanaka, Benjamin Nicholson, Journal of Medicinal Chemistry Pharmaceutical ScienceOrganic ChemistryMicrotubule DepolymerizationPharmaceutical ChemistryMedicinal Chemistry	2011	104
Salinosporamides D−J from the Marine Actinomycete <i>Salinispora tropica</i>, Bromosalinosporamide, and Thioester Derivatives Are Potent Inhibitors of the 20S Proteasome Katherine A. Reed, Rama Rao Manam, Scott S. Mitchell, Journal of Natural Products Salinosporamides FMedicinal ChemistryMarine BiotechnologyBiosynthesisPharmaceutical Science	2007	87
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen Jennifer R. Riggs, Mark A. Nagy, Jan Elsner, Journal of Medicinal Chemistry Breast OncologyPharmaceutical ChemistryTumor BiologyMedicinal ChemistryOncology	2017	59
Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint Dan Zhu, Shuichan Xu, Gordafaried Deyanat‐Yazdi, Molecular Cancer Therapeutics	2018	35
Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth Dan Zhu, Jennifer L. Hensel, Robert Hilgraf, Molecular and Cellular Biochemistry Tumor BiologySignal TransductionCell RegulationReceptor Tyrosine KinaseCell Proliferation	2009	32
Tubulin Photoaffinity Labeling with Biotin‐Tagged Derivatives of Potent Diketopiperazine Antimicrotubule Agents Yuri Yamazaki, Kyoko Kohno, Hiroyuki Yasui, ChemBioChem	2008	17

Page 1